Singapore: Germany Trade & Invest and the Health-Made in Germany initiative will join forces at this year's BioJapan...
Tokyo: The 7th in-Pharma Japan and 26th Interphex Japan, which are being concurrently held at Tokyo Big Sight, Japan, k...
Singapore: Breaking its silence for the first time in 10 days after Indian drug major Ranbaxy's $500 million settlement ...
Singapore: Researchers from the Riken HPCI Program for Computational Life Sciences, the Okinawa Institute of Technology...
Singapore: Seegene, a leading developer of multiplexed molecular technologies and diagnostic tests, has entered into a c...
Singapore: Reverse Medical announced entering into a strategic partnership agreement with Century Medical (CMI), for dis...
Singapore: Astellas Pharma, US, a US subsidiary of Tokyo-based Astellas Pharma, received US FDA acceptance for review o...
Singapore: Dainippon Sumitomo Pharma (DSP), headquartered in Japan, and Nippon Shinyaku, also a Japanese company, have c...
Singapore: Takeda Pharmaceutical's Azilva (azilsartan) is now available for the treatment of hypertension in Japan. Disc...
Singapore: Japan's Ministry of Health, Labor and Welfare has approved the use of Humira in induction and maintenance of ...
Singapore: Takeda Pharmaceuticals, US, highlighted that in the case against Jack Cooper (No CGC-12-518535) the jury rule...
Singapore: Life Technologies has extended its collaborative agreement with Japanese firm DNAVec Corporation to launch Cy...
Telemedicine is re-defining access to healthcare in many ways. It has, in particular, proved to be an effective solution...
Singapore: The US FDA has approved Teva Pharmaceutical's Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradi...
Singapore: Japan's pharmaceutical market was estimated to be worth $89.1 billion in 2012 and is expected to reach approx...
Singapore: Evolva Holding SA entered into a collaboration agreement with Ajinomoto, Japan, for the joint development of ...
Singapore: Tokyo-headquartered Astellas Pharma and Sanwa Kagaku Kenkyusho, based in Nagoya, Japan, have launched a hyper...
Singapore: Sanofi has submitted the marketing authorization application for Lyxumia, (lixisenatide), an investigational ...
